This thesis reviews various molecular targets that have an effect in Traumatic Brain Injury. It focuses on the secondary phase of injury, from acute to chronic stages, and touches on the different roles of receptors, active and passive molecules and various cells that create that environment. It highlights the various studied medications and their effects on neuro-protection, as well as neuro-support. It compares some targets and questions their combination effects, synergistic and additive. It questions what we have discovered so far, in Food and Drug Administration (FDA) approved drugs, and questions the potential of other drugs in such a category for future use in Traumatic Brain Injury. The conclusion points to the possibility of having effective combination drugs with low side effect profiles, personalized to patients with Traumatic Brain Injury to ameliorate long term sequelae.